Joyce James

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

Patrick P. Zarrinkar, Ruwanthi N. Gunawardane, Merryl Cramer et al. · Blood · 2009 · 630 citations · Full text

Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status

Jörge E. Cortes, Hagop M. Kantarjian, James M. Foran et al. · Journal of Clinical Oncology · 2013 · 358 citations · Full text

Identification of <i>N</i>-(5-<i>tert</i>-Butyl-isoxazol-3-yl)-<i>N</i>′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-<i>b</i>][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor

Qi Chao, Kelly G. Sprankle, Robert M. Grotzfeld et al. · Journal of Medicinal Chemistry · 2009 · 189 citations · Full text

Drug Target, Aml Patients, Pharmacotherapy +20

Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin

Brian Metcalf, Chih-Yuan Chuang, Kobina Dufu et al. · ACS Medicinal Chemistry Letters · 2017 · 183 citations · Full text

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.

Jörge E. Cortes, James M. Foran, Darejan Ghirdaladze et al. · Blood · 2009 · 66 citations